It is very uncertain whether avoralstat changes serious adverse events (during compared with placebo (very low certainty).
Lanadelumab showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).
It is very uncertain whether meropenem changes serious adverse events maximum compared with standard care (very low certainty).
It is very uncertain whether vancomycin plus gentamicin changes serious adverse events maximum compared with vancomycin plus aztreonam (very low certainty).
It is very uncertain whether cefazolin plus amikacin changes serious adverse events maximum compared with vancomycin plus amikacin (very low certainty).
It is very uncertain whether ticarcillin plus clavulanic acid changes serious adverse events maximum compared with flucloxacillin and gentamicin (very low certainty).
It is very uncertain whether cloxacillin plus amikacin changes serious adverse events maximum compared with cefotaxime plus gentamicin (very low certainty).
It is very uncertain whether piperacillin changes serious adverse events maximum compared with ampicillin plus amikacin (very low certainty).
It is very uncertain whether ampicillin plus gentamicin changes serious adverse events maximum compared with penicillin plus gentamicin (very low certainty).
It is very uncertain whether piperacillin plus tazobactam changes serious adverse events maximum compared with amikacin (very low certainty).
It is very uncertain whether ticarcillin plus clavulanic acid changes serious adverse events maximum compared with piperacillin plus gentamicin (very low certainty).
It is very uncertain whether cefepime changes serious adverse events Maximum compared with ceftazidime (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether mirtazapine changes safety: serious adverse events compared with placebo (very low certainty).
Probiotics used as adjuvants to conventional antifungal drugs showed no clear difference in rate of serious adverse events compared with conventional antifungal drugs (low certainty).